Biotechnology · Healthcare
CFO
Equibles does not estimate personal net worth.
Keith Goldan is recorded as CFO at Option Therapeutics Inc. (OPTN) and CFO at Syndax Pharmaceuticals Inc (SNDX). The proxy statement of Syndax Pharmaceuticals Inc reports total compensation of $2,470,802 for Keith Goldan in fiscal 2025, including a base salary of $516,900. Disclosed compensation is on record for 4 fiscal years. Keith Goldan has spoken on 20 earnings calls across 2 companies, most recently for Syndax Pharmaceuticals Inc on August 4, 2026. Those appearances were for Syndax Pharmaceuticals Inc (SNDX) and Option Therapeutics Inc. (OPTN). Syndax Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Syndax Pharmaceuticals Inc includes Michael A. Metzger (CEO and Board Member), Michael Metzger (CEO), Aaron A. Ondrey (CFO and Chief Accounting Officer) and 6 others.
“Earlier this afternoon, we reported detailed second quarter 2026 financial results, and I'll highlight a few key points on slide 12. Total revenue for the second quarter of 2026 was $72.8 million, up 92% over the same period last year.”
“Earlier this afternoon, we reported detailed fourth quarter and full year 2025 financial results. I'll highlight just a few key points on slide 14.”
“Earlier this afternoon, we reported detailed third quarter 2025 financial results. I will touch on a few key points on Slide 14. For the third quarter of 2025, we reported Revuforj net revenue of $32 million.”
“Earlier this afternoon, we reported detailed second quarter 2025 financial results, and I'll touch on a few of these key points on Slide 12. For the second quarter of 2025, we reported Revuforj net revenue of $28.6 million.”
“Earlier this afternoon, we reported detailed first quarter 2025 financial results in our press release and Form 10-Q. For today's call, I'll touch upon a few key points on slide 12.”
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Syndax Pharmaceuticals Inc (SNDX) | Chief Financial Officer | $516,900 | $2,470,802 |
| 2024 | Syndax Pharmaceuticals Inc (SNDX) | Chief Financial Officer | $497,000 | $2,824,133 |
| 2023 | Syndax Pharmaceuticals Inc (SNDX) | Chief Financial Officer | $470,300 | $2,826,034 |
| 2022 | Syndax Pharmaceuticals Inc (SNDX) | Chief Financial Officer | $249,900 | $2,992,538 |